Live Breaking News & Updates on Healio Gastroenterology

Stay updated with breaking news from Healio gastroenterology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Q&A: Longest survival among HCC patients seen with 'breakthrough' drug combination


Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
Healio Gastroenterology,
Richard Finn, MD, discussed the results from a recent study of patients with hepatocellular carcinoma treated with combination therapy comprising atezolizumab, an immunotherapy drug and monoclonal antibody, and bevacizumab, another monoclonal antibody against the vascular endothelial growth factor (VEGF).
The data presented at the Digital Liver Cancer Summit 2021 was an update to a trial initially published with 8.6-months follow-up published in
The
New England Journal of Medicine. Finn, professor in the department of medicine, division of hematology/oncology, director of signal transduction and therapeutics program at the Jonsson Comprehensive Cancer at the Geffen School of Medicine at University of California, Los Angeles, and colleagues included 501 pa ....

Roche Genentech , Richard Finn , Los Angeles , Monica Stonehill , Eli Lilly , Bristol Myers Squibb , Digital Liver Cancer Summit , Pfizer Merck , Bristol Myers , Healio Gastroenterology , New England Journal , Jonsson Comprehensive Cancer , Geffen School , ரோச் ஜெநிஂடெக் , ரிச்சர்ட் ஃபிந் , லாஸ் ஏஞ்சல்ஸ் , மோனிகா ஸ்டொன்ெஹில்ல் , எலி லில்லி , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , டிஜிட்டல் கல்லீரல் புற்றுநோய் உச்சிமாநாடு , ஃபைசர் மெர்க் , பிரிஸ்டல் மைஸ் , புதியது இங்கிலாந்து இதழ் , ஜான்சன் விரிவான புற்றுநோய் , கெஃப்ஃபெந் பள்ளி ,